JP2024517695A5 - - Google Patents
Info
- Publication number
- JP2024517695A5 JP2024517695A5 JP2023565518A JP2023565518A JP2024517695A5 JP 2024517695 A5 JP2024517695 A5 JP 2024517695A5 JP 2023565518 A JP2023565518 A JP 2023565518A JP 2023565518 A JP2023565518 A JP 2023565518A JP 2024517695 A5 JP2024517695 A5 JP 2024517695A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pyrrolidine
- fluorotetrahydro
- diazabicyclo
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163181625P | 2021-04-29 | 2021-04-29 | |
| US63/181,625 | 2021-04-29 | ||
| US202163277309P | 2021-11-09 | 2021-11-09 | |
| US63/277,309 | 2021-11-09 | ||
| PCT/US2022/026623 WO2022232331A1 (en) | 2021-04-29 | 2022-04-28 | Heterocyclic compounds and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517695A JP2024517695A (ja) | 2024-04-23 |
| JP2024517695A5 true JP2024517695A5 (https=) | 2025-05-08 |
Family
ID=83847330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565518A Pending JP2024517695A (ja) | 2021-04-29 | 2022-04-28 | 複素環式化合物及び使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250059205A1 (https=) |
| EP (1) | EP4329757A4 (https=) |
| JP (1) | JP2024517695A (https=) |
| AU (1) | AU2022264784A1 (https=) |
| CA (1) | CA3217856A1 (https=) |
| MX (1) | MX2023012726A (https=) |
| WO (1) | WO2022232331A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019195609A2 (en) | 2018-04-04 | 2019-10-10 | Arvinas Operations, Inc. | Modulators of proteolysis and associated methods of use |
| CN117659051A (zh) * | 2021-03-30 | 2024-03-08 | 上海德琪医药科技有限公司 | Kras g12d蛋白抑制剂和其用途 |
| WO2023114733A1 (en) * | 2021-12-13 | 2023-06-22 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| CN118510785B (zh) * | 2021-12-28 | 2025-03-18 | 凌科药业(杭州)有限公司 | 一种含氮杂环化合物及其应用 |
| CN118556063A (zh) * | 2022-01-21 | 2024-08-27 | 上海湃隆生物科技有限公司 | 杂环类化合物、药物组合物及其应用 |
| CA3243798A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras Modulators and Their Uses |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| CN118434748A (zh) * | 2022-04-15 | 2024-08-02 | 杭州多域生物技术有限公司 | 一种六元并六元化合物、制备方法、药物组合物和应用 |
| WO2023230190A1 (en) | 2022-05-25 | 2023-11-30 | Quanta Therapeutics, Inc. | Pyrimidine based modulators and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2023244713A1 (en) * | 2022-06-16 | 2023-12-21 | Ensem Therapeutics, Inc. | Quinazoline derivatives, compositions and methods thereof |
| WO2024022444A1 (zh) | 2022-07-27 | 2024-02-01 | 江苏恒瑞医药股份有限公司 | 稠环类化合物、其制备方法及其在医药上的应用 |
| CN119790059A (zh) * | 2022-08-30 | 2025-04-08 | 上海科州药物股份有限公司 | 作为kras抑制剂的杂环化合物，及其制备和治疗用途 |
| US12448399B2 (en) | 2023-01-26 | 2025-10-21 | Arvinas Operations, Inc. | Cereblon-based KRAS degrading PROTACs and uses related thereto |
| KR20260041941A (ko) | 2023-03-15 | 2026-03-27 | 콴타 테라퓨틱스, 인크. | Kras 조절 인자 및 이의 용도 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| EP4735453A1 (en) * | 2023-06-30 | 2026-05-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| TW202529804A (zh) | 2023-10-06 | 2025-08-01 | 美商安進公司 | 用於癌症治療的組合療法 |
| US20250114339A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy comprising a kras g12d inhibitor and an egfr inhibitor |
| US20250114346A1 (en) | 2023-10-09 | 2025-04-10 | Incyte Corporation | Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107082779A (zh) * | 2012-03-30 | 2017-08-22 | 理森制药股份公司 | 作为c‑met 蛋白激酶调节剂的新化合物 |
| WO2016049568A1 (en) * | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Methods and compositions for inhibition of ras |
| WO2017172979A1 (en) * | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| WO2017192840A1 (en) * | 2016-05-04 | 2017-11-09 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US10745385B2 (en) * | 2017-05-25 | 2020-08-18 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| WO2019115586A1 (en) * | 2017-12-12 | 2019-06-20 | Phenex Discovery Verwaltungs-GmbH | Oxalamides as modulators of indoleamine 2,3-dioxygenase |
| PE20260440A1 (es) * | 2018-11-09 | 2026-02-19 | Hoffmann La Roche | Compuestos de anillo fusionado |
| CN112110918B (zh) * | 2019-06-21 | 2023-08-22 | 劲方医药科技(上海)有限公司 | 螺环取代的嘧啶并环类化合物，其制法与医药上的用途 |
| MX2022002465A (es) * | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| CA3177261A1 (en) * | 2020-04-29 | 2021-11-04 | Shanghai Ringene Biopharma Co., Ltd. | Benzothiazolyl biaryl compound, and preparation method and use |
| WO2022002102A1 (en) * | 2020-06-30 | 2022-01-06 | InventisBio Co., Ltd. | Quinazoline compounds, preparation methods and uses thereof |
| CA3191279A1 (en) * | 2020-08-28 | 2022-03-03 | Yi Liu | Heterocyclic compounds and uses thereof |
| KR20230136636A (ko) * | 2021-02-09 | 2023-09-26 | 메드샤인 디스커버리 아이엔씨. | 피리미딘 방향족 환 화합물 |
| EP4291199A4 (en) * | 2021-02-09 | 2025-06-18 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| BR112023016299A2 (pt) * | 2021-02-16 | 2023-11-28 | L Livermore Nat Security Llc | Composições e métodos para inibir kras |
| JP2024510207A (ja) * | 2021-03-12 | 2024-03-06 | ブリストル－マイヤーズ スクイブ カンパニー | Ｋｒａｓ阻害剤 |
| MX2023010430A (es) * | 2021-03-12 | 2023-09-12 | Bristol Myers Squibb Co | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d). |
| MX2023012725A (es) * | 2021-04-29 | 2024-09-23 | Amgen Inc | Compuestos de 2-aminobenzotiazol y metodos de uso de los mismos. |
-
2022
- 2022-04-28 US US18/696,946 patent/US20250059205A1/en active Pending
- 2022-04-28 AU AU2022264784A patent/AU2022264784A1/en active Pending
- 2022-04-28 JP JP2023565518A patent/JP2024517695A/ja active Pending
- 2022-04-28 EP EP22796686.8A patent/EP4329757A4/en active Pending
- 2022-04-28 WO PCT/US2022/026623 patent/WO2022232331A1/en not_active Ceased
- 2022-04-28 CA CA3217856A patent/CA3217856A1/en active Pending
- 2022-04-28 MX MX2023012726A patent/MX2023012726A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024517695A5 (https=) | ||
| JP2024532735A5 (https=) | ||
| JP2025508703A5 (https=) | ||
| JP2024532733A5 (https=) | ||
| EP4301363A1 (en) | Quinazoline amine derivatives as kras inhibitors | |
| ES2908283T3 (es) | Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades | |
| EP3468972B1 (en) | Compounds and compositions for inhibiting the activity of shp2 | |
| ES2796285T3 (es) | Indazoles sustituidos, procedimientos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| KR102014326B1 (ko) | 벤즈옥사제핀 옥사졸리디논 화합물 및 사용 방법 | |
| JP2024532734A5 (https=) | ||
| KR102304108B1 (ko) | 림프종 치료를 위한 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린의 용도 | |
| UA128160C2 (uk) | Сполуки, що інгібують rip1, а також способи їх одержання та застосування | |
| CN108884098B (zh) | 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类 | |
| WO2022187527A1 (en) | Quinazoline nitrile derivatives as kras inhibitors | |
| AU2013249280A1 (en) | Compounds and methods for antiviral treatment | |
| EP3233852A1 (en) | TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | |
| WO2024138486A1 (en) | Tetracyclic derivatives as kras inhibitors | |
| EP3310779A1 (en) | Compounds and compositions for inhibiting the activity of shp2 | |
| WO2016040848A1 (en) | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | |
| CN103889428A (zh) | 乙型肝炎病毒抗原分泌的新型抑制剂 | |
| WO2015073267A1 (en) | Substituted heteroaryl compounds and methods of use | |
| JP7254076B2 (ja) | 置換ヘテロアリール化合物及び使用方法 | |
| JP2025072429A (ja) | 骨髄増殖性腫瘍を治療する方法 | |
| WO2015094803A1 (en) | Substituted heteroaryl compounds and methods of use | |
| JP2023522045A (ja) | アリール炭化水素受容体モジュレーターとしてのピリドピリミジノン誘導体およびその使用 |